A new kind of oral antibiotic to treat gonorrhea has secured Food and Drug Administration approval, the second time in two days that a new drug for the common sexually transmitted infection has come through licensure.
Neisseria gonorrhoeae, the bacterium that causes gonorrhea, has for decades been evolving to evade the antibiotics used to treat it. The current standard of care — an intramuscular injection of ceftriaxone — is the last antibiotic to reliably treat the infection, and increasingly treatment failures are being reported.
